Novo Nordisk

Trump unveils TrumpRx discounted drugs website

The website is targeted at consumers looking to buy drugs without using insurance

Jay Thyagarajan, senior VP for Apac at Novo Nordisk, says that one way the company intends to manage patent expiries is through continued investments in R&D, including work on novel drug formulations.
TOPLINE

‘Treating obesity for the next 100 years’: Ozempic-maker Novo Nordisk targets tripling of Apac patient base

By sales volumes for its GLP-1 drugs, the company’s largest markets in the region are Australia, Japan, South Korea and India

Under a November deal with the Trump administration, Novo agreed to sell starter doses of their weight-loss pills if approved.

Novo Nordisk shares jump almost 8% after US approves Wegovy pill

The approval gives the drugmaker a first-mover advantage in the race for a potent oral weight-loss medicine

Pop Mart, the Chinese firm behind Labubu dolls (above), is battling a scourge of fake Lafufus that have flooded online marketplaces.
PERSPECTIVE

What Novo Nordisk, OpenAI and Pop Mart have in common

All three have suffered the curse of overnight success

Novo chief executive officer Mike Doustdar has been pushing to rebuild momentum in the company’s pipeline following intense competition in the weight-loss drug market.

Novo gets 15 billion euros of orders for Akero acquisition bonds

This is more than triple the amount the Danish drugmaker is seeking

Pfizer said it would pay US$86.25 per share in cash, a premium of 3.69 per cent to Metsera’s Friday close.

Metsera accepts Pfizer’s US$10 billion bid in ongoing M&A battle

OBESITY drug developer Metsera said on Friday that it had accepted Pfizer’s US$10 billion acquisition offer, in what could spell the end of a bidding war between the New York-based pharma giant and ri...

Novo Nordisk became Europe’s most valuable firm from rapid sales growth of its blockbuster obesity drug Wegovy, but has seen sales growth slow

Novo Nordisk lowers full-year profit guidance in new CEO’s maiden quarter

The firm says it now expects full-year operating profit to grow between 4% and 7% in 2025

The tussle for Metsera began with discussions between the company and potential acquirers in early 2024, with both Pfizer and Novo Nordisk, the maker of Wegovy and Ozempic, expressing interest.

Pfizer sues Metsera, Novo Nordisk over rival obesity drug bid

[BENGALURU] Pfizer on Friday (Oct 31) filed a lawsuit against Metsera and Novo Nordisk, saying Metsera breached its merger agreement obligations in declaring the Danish drugmaker’s US$8.5 billion bid ...

Novo Nordisk has gone from being Europe’s most valuable listed company to losing more than US$300 billion in market value.
THINKING ALOUD

How I knew when to start backing Novo Nordisk’s biggest rival instead

The Danish firm’s complacency is its undoing in the weight-loss drug war